A study on patients in the phase III trial receiving sunitinib or pazopanib shows poor outcomes for a cluster of patients with a high immune infiltration (especially macrophages) and significantly higher PD-L1 expression on tumor cells compared to the other clusters [38]. Here, CD274 is linked to neoplasm.